Prognostic significance of estrogen and progesterone receptors in stage ii breast cancer

✍ Scribed by Stefan Rydén; Mårten Fernö; Åke Borg; Larsolof Hafström; Torgil Möller; Allan Norgren

• Publisher: John Wiley and Sons
• Year: 1988
• Tongue: English
• Weight: 527 KB
• Volume: 37
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.2930370402

✦ Synopsis

Estrogen (ER) and progesterone receptors (PgR) were evaluated in samples from primary tumors in 539 patients with stage I1 breast cancer participating in a randomized multicenter controlled clinical trial on adjuvant therapy. At the cut-off points of 10 fmol EWmg protein and 30 fmol PgR/ mg protein, no significant difference in recurrence-free survival (RFS) existed between premenopausal patients with receptor-positive and negative tumors, respectively. After recurrence, premenopausal patients with receptor-positive tumors had a significant longer survival than patients with receptor-negative tumors. In postmenopausal patients not treated with adjuvant tamoxifen, no correlations between RFS and receptor status were found. Patients with ER + tumors survived longer than patients with ERtumors. In postmenopausal patients treated with adjuvant tamoxifen, highly significant differences in RFS and in survival were observed when receptor-positive patients were compared with receptor-negative patients. No differences in survival after recurrence were registered among these patients.